Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease: a cross-sectional analysis.

Abdulrahman Ismaiel Mihail Spinu Carmen SocaciuLivia BudisanDaniel-Corneliu Leucuta Stefan-Lucian PopaBogdan Augustin ChisIoana Berindan Neagoe Dan-Mircea Olinic Dan L Dumitrascu

Published in: Nutrition & diabetes (2022)

MAFLD patients are at risk for developing cardiac systolic and subclinical systolic dysfunctions, as well as diastolic dysfunction. Decreased glycyl tyrosine levels correlate with reduced LVEF and LPC (18:2/0:0) levels with diastolic dysfunction, even after adjusting for confounding factors, suggesting their potential to be used as metabolic biomarkers in detecting cardiovascular risk.

Keyphrases

left ventricular
blood pressure
ejection fraction
oxidative stress
end stage renal disease
newly diagnosed
chronic kidney disease
peritoneal dialysis
risk assessment
patient reported outcomes
human health
atrial fibrillation